Johnson & Johnson Aktie News

At 24/7 Wall St., we have focused on dividend stocks for over 15 years because, despite the stock market's ups and downs, many people need solid passive income streams to supplement their income from employment or other sources.

Johnson & Johnson's latest dividend declaration translates into an annual growth rate of 4.47%. This is the lowest level in at least 10 years, signaling ongoing growth pressures. Mixed Q3 earnings results and Q4 outlook suggest profit headwinds and rising payout ratios, further limiting room for future dividend increases.

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring   Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time  HORSHAM, Pa. , Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2  In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies a...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi's 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition...

There were rumors that the FDA was going to warn pregnant women against using Tylenol. When the news finally hit, Tylenol maker Kenvue's stock had already fallen a great deal.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW, and IBM have delivered strong double-digit returns this year. Dividend growth for the Aristocrats in 2025 averages 5.27%, with most constituents raising payouts, though growth may not exceed 2024...